- Home
- SOR vs PRTC Comparison
SOR vs PRTC Comparison
Compare SOR & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- PRTC
- Stock Information
- Founded
- SOR 1968
- PRTC 2015
- Country
- SOR United States
- PRTC United States
- Employees
- SOR N/A
- PRTC N/A
- Industry
- SOR Investment Managers
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- PRTC Health Care
- Exchange
- SOR Nasdaq
- PRTC Nasdaq
- Market Cap
- SOR 368.8M
- PRTC 355.3M
- IPO Year
- SOR N/A
- PRTC N/A
- Fundamental
- Price
- SOR $45.00
- PRTC $14.70
- Analyst Decision
- SOR
- PRTC
- Analyst Count
- SOR 0
- PRTC 0
- Target Price
- SOR N/A
- PRTC N/A
- AVG Volume (30 Days)
- SOR 16.2K
- PRTC 5.9K
- Earning Date
- SOR 01-01-0001
- PRTC 08-28-2025
- Dividend Yield
- SOR 7.24%
- PRTC N/A
- EPS Growth
- SOR N/A
- PRTC N/A
- EPS
- SOR 6.50
- PRTC 0.20
- Revenue
- SOR N/A
- PRTC $6,391,000.00
- Revenue This Year
- SOR N/A
- PRTC N/A
- Revenue Next Year
- SOR N/A
- PRTC N/A
- P/E Ratio
- SOR $6.41
- PRTC $6.88
- Revenue Growth
- SOR N/A
- PRTC 1265.60
- 52 Week Low
- SOR $36.41
- PRTC $13.30
- 52 Week High
- SOR $42.75
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- SOR 61.45
- PRTC 31.28
- Support Level
- SOR $44.69
- PRTC $15.75
- Resistance Level
- SOR $45.74
- PRTC $16.75
- Average True Range (ATR)
- SOR 0.57
- PRTC 0.48
- MACD
- SOR 0.01
- PRTC -0.20
- Stochastic Oscillator
- SOR 52.05
- PRTC 5.73
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.